Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662996 | 0.78 | TSHR (0.41) | TSHRPDE4BPDE4DKDM2BHPGD | |
| SCHEMBL16995116 | 0.78 | CA9 (0.41) | PDE4BPDE4DPOLBSMN1; SMN2KMT2A | |
| SCHEMBL4969142 | 0.78 | CA12 (0.53) | HPGDPOLBSMN1; SMN2KMT2A | |
| SCHEMBL31507349 | 0.78 | CA9 (0.41) | PDE4BPDE4DPOLBSMN1; SMN2KMT2A | |
| SCHEMBL16198442 | 0.76 | ATR (0.43) | TSHRHPGDPOLBHCRTR1HCRTR2 | |
| SCHEMBL416232 | 0.74 | TYK2 (0.43) | TYK2JAK2JAK1KMT2A | |
| SCHEMBL1168812 | 0.72 | GAA (0.44) | POLBSMN1; SMN2KMT2A | |
| SCHEMBL6823880 | 0.71 | CA12 (0.57) | HPGDPOLBSMN1; SMN2KMT2AMAPT | |
| SCHEMBL31507330 | 0.71 | MEN1 (0.39) | POLBKMT2A | |
| SCHEMBL26670624 | 0.69 | GRM4 (0.40) | TSHRHPGDPOLBSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | CDK1, CDK5, TTBK1 | TSHR 3111/4885PDE4B 970/4885PDE4D 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.